INSM
Insmed Inc
Halal Rating :
Last Price
$72.49
Last updated:
Market Cap
-
7D Change
5.16%
1 Year Change
154.08%
Company Overview
Industries
Exchange
Next Earnings Date
Insmed Incorporated is a global biopharmaceutical company focused on the development and commercialization of therapies for patients with serious and rare diseases. Their lead product ARIKAYCE® (amikacin liposome inhalation suspension) is approved for the treatment of Mycobacterium avium complex (MAC) lung disease. The company is also developing other therapeutic candidates for various rare diseases.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $93.42m | $327.91m | - | $21.05m | 0.00% | 6.42% |
| June 30, 2024 | $90.34m | $400.51m | - | $21.27m | 0.00% | 5.31% |
| March 31, 2024 | $75.5m | $242.05m | - | $21.04m | 0.00% | 8.69% |
Company Impact
Help us evaluate Insmed Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.